Ubs Group Ag Lensar, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Lensar, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 541 shares of LNSR stock, worth $6,930. This represents 0.0% of its overall portfolio holdings.

Number of Shares

541

Previous 554 2.35%

Holding current value

$6,930

Previous $2,000 100.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$4.2 - $8.82 $54 - $114	-13 Reduced 2.35%	541 $4,000
Q2 2024 Aug 13, 2024	SELL	$3.0 - $4.88 $8,469 - $13,776	-2,823 Reduced 83.59%	554 $2,000
Q1 2024 May 13, 2024	BUY	$3.25 - $5.0 $7,884 - $12,130	2,426 Added 255.1%	3,377 $11,000
Q4 2023 Feb 09, 2024	BUY	$2.01 - $3.51 $884 - $1,544	440 Added 86.11%	951 $3,000
Q3 2023 Nov 09, 2023	BUY	$3.02 - $4.45 $984 - $1,450	326 Added 176.22%	511 $1,000
Q4 2022 Feb 08, 2023	SELL	$2.7 - $5.9 $1,017 - $2,224	-377 Reduced 67.08%	185 $0
Q3 2022 Nov 10, 2022	SELL	$4.94 - $7.0 $1,299 - $1,841	-263 Reduced 31.88%	562 $3,000
Q2 2022 Aug 10, 2022	BUY	$6.15 - $7.94 $897 - $1,159	146 Added 21.5%	825 $5,000
Q1 2022 May 16, 2022	SELL	$5.8 - $8.2 $17,579 - $24,854	-3,031 Reduced 81.7%	679 $5,000
Q4 2021 Feb 14, 2022	SELL	$5.9 - $7.84 $259 - $344	-44 Reduced 1.17%	3,710 $23,000
Q3 2021 Nov 15, 2021	SELL	$7.5 - $8.88 $1,162 - $1,376	-155 Reduced 3.97%	3,754 $29,000
Q2 2021 Aug 13, 2021	SELL	$6.87 - $8.66 $37,929 - $47,811	-5,521 Reduced 58.55%	3,909 $34,000
Q1 2021 May 12, 2021	BUY	$6.28 - $9.56 $11,756 - $17,896	1,872 Added 24.77%	9,430 $69,000
Q4 2020 Feb 11, 2021	BUY	$6.7 - $12.2 $50,638 - $92,207	7,558 New	7,558 $54,000

Others Institutions Holding LNSR

# of Institutions

Shares Held

4.72M

Call Options Held

12.2K

Put Options Held

30.6K

View Full List

About LENSAR, Inc.

Ticker LNSR
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 11,021,000
Market Cap $141M
Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in...

More about LNSR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account